TITLE YEAR ENDPOINTS RESULTS CONCLUSION LINK

Cardiovascular 2012 Jan Primary endpoint was a Primary CV events occurred in These results from a large https://pubmed.ncbi.nlm.nih.gov/22234149/
safety with composite of CV death, 11 (0.3%) patients receiving Phase 3 programme support
linagliptin in patients Meta- stroke, myocardial linagliptin and 23 (1.2%) the hypothesis that
with type 2 diabetes Analysis infarction, and receiving comparators (placebo, linagliptin may have CV
mellitus: a pre- hospitalization for glimepiride, voglibose) benefits in patients with
specified, unstable angina T2DM.
prospective, and Primary endpoint showed
adjudicated meta- significantly lower risk with
analysis of a phase 3 linagliptin than comparators
programme

Design and baseline 2015 Primary outcome is time Hierarchical testing for The results of this may https://pubmed.ncbi.nlm.nih.gov/25780262/
characteristics of the May to first occurrence of superiority will follow, and the influence the decision-making
Cardiovascular cardiovascular death, trial has 80% power to process for selecting a second
Outcome Trial of non-fatal myocardial demonstrate a 20% relative glucose-lowering agent after
Linagliptin Versus RCT infarction, non-fatal cardiovascular risk reduction metformin in type 2 diabetes
Glimepiride in Type stroke, or hospitalization
2 Diabetes for unstable angina
(CAROLINA®)